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PCN131
Cost-EffECtivENEss of BENdamustiNE-RituximaB iN fiRst-LiNE 
iNdoLENt NHL: a PatiENt-LEvEL simuLatioN
Dewilde S.1, Woods B.2, Castaigne J.G.3, Parker C.2, Dunlop W.3
1SHE, Brussels, Belgium, 2Oxford Outcomes, Oxford, UK, 3Mundipharma International Limited, 
Cambridge, UK
Objectives: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) 
compared with standard of care as first-line treatment for patients with advanced 
indolent non-Hodgkin’s lymphoma (NHL) in England and Wales. MethOds: A 
patient-level simulation was adapted from the model used by the University of 
Sheffield School of Health and Related Research (ScHARR) in a health technology 
appraisal of rituximab for first-line treatment of follicular lymphoma (the most 
common type of indolent NHL). This approach allowed modelling of the complex 
treatment pathways in indolent NHL; specifically, first-line maintenance and sec-
ond-line treatment choice could be modelled as a function of patient age, and prior 
treatment choice and outcome. Data from a Phase 3 randomised, open-label trial 
by the Study group indolent Lymphomas (StiL) in Germany were used to compare 
B-R with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituxi-
mab). The relative efficacy of CHOP-R and CVP-R (cyclophosphamide, vincristine, 
prednisone, rituximab) was estimated as per the original ScHARR approach. The 
analysis was conducted from the perspective of the National Health Service, using 
a lifetime time horizon. One-way sensitivity and scenario analyses were conducted, 
including one using recently published randomised trial data comparing CVP-R with 
CHOP-R. Results: The base-case deterministic incremental cost-effectiveness ratio 
(ICER) was £5,249 per quality adjusted life year (QALY) for B-R vs. CHOP-R, and £8,092 
per QALY for B-R vs. CVP-R. The alternative scenario using direct data comparing 
CVP-R with CHOP-R more than halved the ICER for B-R vs. CVP-R to £3,468. Owing 
to its better toxicity profile, B-R reduced the cost of treating adverse events by over 
£1,000 per patient vs. CHOP-R. None of the one-way sensitivity or scenario analyses 
increased the ICER above £20,000. cOnclusiOns: The ICERs for B-R vs. CHOP-R and 
CVP-R were below the thresholds normally regarded as cost-effective in England 
and Wales (£20,000 – 30,000 per QALY).
PCN132
Cost-utiLity of GRaNuLoCytE-CoLoNy stimuLatiNG faCtoRs (G-Csfs) 
foR PRimaRy PRoPHyLaxis (PP) of CHEmotHERaPy iNduCEd fEBRiLE 
NEutRoPENia (fN) iN BREast CaNCER PatiENts iN tHE NEtHERLaNds
Somers L.1, Timmer-Bonte J.N.H.2, Gelderblom H.3
1OncoLogX bvba, Wuustwezel, Belgium, 2Alexander Monro Breast Cancer Hospital, Bilthoven, The 
Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands
Objectives: To assess number needed to treat to avoid an episode of FN (NNT) 
and cost-utility in The Netherlands of PP with once-per-cycle pegfilgrastim vs. no 
prophylaxis and vs. PP with daily G-CSF filgrastim (11-days as per label or 6-days 
suboptimal use) for reducing FN incidence in women with primary breast can-
cer receiving high risk chemotherapy for FN (e.g. TAC, a frequently used reference 
regimen in The Netherlands). MethOds: A decision-analytic model was con-
structed from health care-payer perspective. Costs were from official list prices 
(April 2013) or literature and included drugs, drug administration and FN-related 
medical costs and hospitalisations. Effectiveness inputs in terms of relative risk 
reduction (RRR) for FN were based on a recent meta-analysis. Survival and utility 
inputs were modeled from available data for breast cancer patients in the US and 
the UK. Outcomes included NNT and incremental cost effectiveness ratio (ICER) as 
cost per quality-adjusted life-year gained (QALY). Univariate sensitivity analyses 
evaluated the robustness of the model. Results: NNT with pegfilgrastim PP was 
lowest at 4.4, with filgrastim 11-days at 5.6 and filgrastim 6-days at 13.4. In terms 
of cost-utility, pegfilgrastim PP was dominant vs. 11-days filgrastim PP and was 
considered cost-effective vs. no prophylaxis (€ 29,896/QALY) and vs. PP with 6-days 
filgrastim (€ 7,615/QALY). In a scenario analysis reducing the prices of daily G-CSFs 
by 40%, pegfilgrastim PP remained cost-effective. The sensitivity analyses revealed 
that most sensitive variables were FN effectiveness (relative risk reductions), incre-
mental survival assumptions and cost of G-CSFs, and overall the model was robust 
to sensitivity analyses. cOnclusiOns: In a Dutch setting, pegfilgrastim PP offers 
a cost-effective approach to PP of FN. In the cost-utility analysis pegfilgrastim PP 
was dominant vs. 11-days filgrastim PP and cost-effective vs. no prophylaxis and 
6-days filgrastim PP.
PCN133
Cost-EffECtivENEss aNaLysis of aBiRatERoNE aCEtatE as sECoNd LiNE 
tREatmENt foR mEtastatiC CastRatioN-REsistaNt PRostatE CaNCER 
aftER doCEtaxEL tREatmENt iN JaPaN
Shibahara H.1, Shiroiwa T.2, Nakamura K.1, Shimozuma K.1
1Ritsumeikan University, Kusatsu, Japan, 2National Institute of Public Health, Saitama, Japan
Objectives: Abiraterone acetate improves overall survival of patients with meta-
static castration-resistant prostate cancer (CRCP). The NICE in the UK has recom-
mended abiraterone as a second line treatment for CRCP after docetaxel. Ministry 
of Health, Labour and Welfare (MHLW) has begun to discuss whether or how to use 
cost-effectiveness data for reimbursement or pricing. The purpose of this study is 
to evaluate cost-effectiveness of abiraterone plus prednisolone compared to pred-
nisolone alone in Japan. MethOds: Cost-effectiveness analysis was performed 
using a Markov model (TreeAge Pro 2013) based on data from the randomized control 
trial (COU-AA-301 study) and literature review conducted from the public health 
care payer’s perspective. The (1) abiraterone (1,000 mg once daily and orally) plus 
prednisolone (5 mg twice daily and orally) was compared with (2) prednisolone 
alone. The base case was assumed to be a 69 year-old man with metastatic CRPC. 
The model used a time horizon of 10 years. Outcomes were measured in quality-
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. MHLW has yet to approve abiraterone due to the delay in development, 
and drug cost was estimated based on prices in the UK and the US. Both cost and 
outcomes were discounted at a 2% annual rate based on Japanese guidelines for eco-
Objectives: To summarize the modeling methods used in published 
cost-effectiveness evaluations of first-line treatment for advanced NSCLC 
patients. MethOds: To identify relevant studies, a systematic literature search 
was performed in Medline®, EMBASE®, Medline-In-Process and the CRD data-
base from 2000 to 2013. In addition, Technology Appraisals (TA) were identified by 
searching the NICE, SMC and pCODR websites. Studies were included for review 
based on the following pre-defined criteria; 1) description of cost-effectiveness or 
cost-utility analysis; 2) inclusion of a comparison of drug interventions in first-line 
treatment of advanced NSCLC patients; and 3) results were expressed as cost per 
LY or QALY gained. Results: Out of 1009 unique citations, 21 publications and 
18 TA met the inclusion criteria. The identified cost-utility and cost-effectiveness 
analyses were all performed from a payer perspective for a variety of countries in 
Europe, Asia and North America. The economic value of targeted therapies for first-
line and maintenance treatment for advanced NSCLC patients were evaluated for 
different subpopulations according to histology type (non-squamous, squamous). 
The most commonly used modeling approach was the state-transition model 
with health states reflecting stable disease, progression, and death. Transitions 
between these health states were based on either fixed or time varying transition 
probabilities. Cost-effectiveness analyses that were based on a synthesis of clinical 
efficacy evidence primarily relied on the constant hazard ratio assumption. The 
impact of structural modeling assumptions on cost-effectiveness findings was 
frequently not reported. cOnclusiOns: Based on a review of published cost-
effectiveness evaluations, it was concluded that the rational for certain modeling 
choices are frequently not provided. In particular, choices pertaining to methods 
for clinical evidence synthesis and the impact on cost-effectiveness findings need 
to be justified in a more structured way.
PCN129
Cost-miNimizatioN aNaLysis (Cma) of diffERENt stRatEGiEs to tREat 
NEwLy diaGNosEd LoCaLLy CoNfiNEd Low-Risk PRostatE CaNCER 
(LCLRPC) iN GERmaNy: REsuLts of tHE HaRow study
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for the about 64,000 men diagnosed 
with prostate cancer each year in Germany still remains unclear. The objectives 
therefore were to estimate and compare costs under day-to-day conditions of car-
ing for men in Germany with newly diagnosed LCLRPC using hormonal therapy 
(HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watchful waiting 
(WW) – HAROW. MethOds: The long-term observational multi-centre HAROW 
study combined data collection from urologists (clinical data; utilized outpatient 
medical services, OMS) and from patients (employment status, QoL by EQ-5D, 
numerous health resource use items). Resource use was valued by year 2010 offi-
cial prices in € . Direct costs (DC) were given by hospital treatment, OMS and drugs, 
inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: sick leave, pre-
mature retirement, premature mortality) were estimated by 2010 gross domestic 
product/capita/day. Costs and quality-adjusted life-years (QALYs) were discounted 
by 3% per annum. Strategies without significant differences in QALYs/patient-year 
(PY) were compared by cost-minimization analysis (CMA) using mean costs/PY, 
remaining strategies by cost-utility analysis. Results: From 07/2008 to 03/2013, 
3063 LCLRPC patients (T1a–T2c, N0, M0; 67.3±7.5 years) were included from 257 
urologists: AS n= 452, RT n= 378, HT n= 210, HT+RT n= 80, combination therapy (CT) 
n= 137, OP n= 1647, other therapy (OT) n= 18, WW n= 141. Observation period: aver-
age 1.9 years, maximum 4.6 years. From the societal perspective (DC+IC), HT+RT 
had the lowest cost/PY (€ 1033), followed by AS (€ 1265), RT (€ 1313), WW (€ 1316), 
HT (€ 1522), CT (€ 3209), OT (€ 5705), and OP had highest cost/PY (€ 6656). From the 
perspective of DC, WW showed he lowest cost/PY (€ 894), followed by RT (€ 905), 
HT+RT (€ 987), AS (€ 1014), HT (€ 1169), OT (€ 2176), CT (€ 2204), and OP had highest 
cost/PY (€ 5374). cOnclusiOns: The HAROW study provides meaningful results 
on costs of different LCLRPC treatment strategies under day-to-day conditions of 
care in Germany to support decision making.
PCN130
HEaLtH tECHNoLoGy assEssmENt of CoNtRast-ENHaNCEd uLtRasouNd 
(CEus) tECHNiquEs
Dozsa C.1, Nagy J.2, Borcsek B.3
1University of Miskolc, Miskolc, Hungary, 2Medience Ltd., Tokol, Hungary, 3Med-Econ Ltd., Veroce, 
Hungary
The second generation of contrast-enhanced ultrasound (CEUS) techniques com-
bines the advantages of ultrasound techniques and the additional information 
provided by the contrast agent. Objectives: To prove that sulphur hexafluoride 
microbubbles contrast agent used for CEUS is as effective in detecting and ana-
lyzing abnormal-looking areas in the liver as currently used imaging techniques 
(contrast-enhanced CT and MRI: CECT and CEMRI), however the costs of CEUS are 
considerably lower. MethOds: Cost-minimization analysis was based on litera-
ture review (last 5 years MEDLINE research, evidence level 1++) and on Hungarian 
financing data. National medical protocols were also considered. Results: Average 
cost per patient of CEUS was 64,5 EUR, while costs of currently used techniques 
were 129 EUR. According to the literature 70% of currently used CT and MRI tech-
niques could be replaced by CEUS. Results made it evident that the equally effective 
contrast-enhanced ultrasound technique is more cost-effective than the currently 
used contrast-enhanced CT and MRI techniques. Health technology assessment 
suggested that the change for the new technology would save 64 509 million EUR 
for the National Health Insurance Fund at the end of the third year of application, 
counting with 5000 cases. cOnclusiOns: The widespread use of cost-effective 
CEUS technology is highly recommended as it is an evidently cost-saving technique 
from the insurer’s point of view. Further assessment is recommended to measure 
clinical parameters, burden of radiology and other quality of life parameters of 
patients, possibly by using a control group if this is ethically viable.
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OMS and drugs, inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: 
sick leave, premature retirement, premature mortality) were estimated by 2010 
gross domestic product/capita/day. Costs and quality-adjusted life-years (QALYs) 
were discounted by 3% per annum. Strategies with significantly different QALYs/
patient-year (PY) were compared by CUA, remaining strategies by cost-minimization 
analysis. Results: From July 2008 to March 2013, 3063 LCLRPC patients (T1a–T2c, 
N0, M0; 67.3±7.5 years) were included from 257 urologists: AS n= 452, RT n= 378, HT 
n= 210, HT+RT n= 80, combination therapy (CT) n= 137, OP n= 1647, other therapy 
(OT) n= 18, WW n= 141. Observation period: average 1.9 years, maximum 4.6 years. 
From the societal perspective (DC+IC), AS and RT each dominated HT, i.e. there 
were savings/PY (€ 257 and € 208) and QALYs gained/PY (0.0811 and 0.0587) with AS 
and RT, respectively, versus HT. When comparing OP to HT, there were additional 
cost (DC+IC) of € 5134/PY and 0.0784 QALYs gained/PY for OP versus HT leading to 
€ 65,525 per QALY gained. cOnclusiOns: The HAROW study provides meaningful 
results on cost utility of AS, OP, RT, and HT as LCLRPC treatment strategies under 
day-to-day conditions of care in Germany to support decision making.
PCN137
a Cost-utiLity aNaLysis of EvERoLimus PLus ExEmEstaNE foR tHE 
tREatmENt of ER+ HER2- mEtastatiC BREast CaNCER iN tHE uNitEd 
kiNGdom
Taylor M.1, Lewis L.2, Vieira J.3, Chandiwana D.3
1York Health Economics Consortium, York, UK, 2York Health Economics Consortium, University of 
York, York, UK, 3Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, UK
Objectives: This study evaluated the cost-effectiveness of everolimus + exemes-
tane (EVE+EXE) versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- 
metastatic breast cancer in the UK. Whilst the effectiveness of treatment has been 
demonstrated previously, this is the first analysis to assess the cost of the intervention 
alongside those benefits. MethOds: A Markov model was developed to compare 
treatment with EVE+EXE versus PBO+EXE in patients with ER+ HER2- metastatic 
breast cancer over a lifetime time horizon (UK health care perspective). Follow-up data 
on progression-free survival and overall survival were taken from the BOLERO II trial. 
Weibull functions were used to extrapolate trial data beyond the follow-up period. 
Utilities from published sources were combined with trial data to calculate quality-
adjusted life years (QALYs) associated with each treatment. Drug costs (list prices) and 
background health state costs (i.e. non-intervention costs) were applied to calculate 
incremental costs offset. Results: Over a ten year time horizon, EVE+EXE led to a 
life expectancy of 3.27 years, compared to 2.41 for PBO+EXE. EVE+EXE resulted in 1.91 
QALYs, compared to 1.31 for PBO+EXE. Therefore, the incremental gains in life years 
and QALYs were 0.85 and 0.60 respectively. Drug costs were £22,074 and £628 for the 
two arms respectively, whilst non-drug costs were £22,332 and £21,108 respectively. 
Therefore, the EVE+EXE arm had an incremental cost of £22,670. The incremental cost 
per QALY was, therefore, £37,719 over a ten-year time horizon. Probabilistic sensitivity 
analysis demonstrated that, at a threshold of £30,000 per QALY gained, EVE+EXE had 
a 27.3% likelihood of being cost-effective. At a threshold of £55,000 per QALY gained, 
the likelihood of cost-effectiveness was 77.4%. cOnclusiOns: EVE+EXE was associ-
ated with increased health care costs, but was also estimated to lead to health gains 
in terms of both LYs and QALYs.
PCN138
Cost-EffECtivENEss of GEmCitaBiNE PLus CisPLatiN vERsus GEmCitaBiNE 
aLoNE foR tREatmENt of advaNCEd BiLiaRy tRaCt CaNCER iN JaPaN
Arakawa I.1, Uemura S.1, Murasawa H.1, Inoue T.2
1Teikyo Heisei University, Tokyo, Japan, 2Tokyo Women’s Medical University, Tokyo, Japan
Objectives: Gemcitabine plus cisplatin is a common use for chemotherapy 
patients with advanced biliary tract cancer in Japan. This study aims to assess the 
cost-effectiveness of this combination therapy compared to monotherapy for bil-
iary tract cancer in Japan. MethOds: A Markov model of three states and monthly 
transmissions was constructed based on a phase II trial. Transition probabilities 
between states were derived from the trial conducted by Valle, J. et al (2010). and 
converted to appropriate parameters for input into the model. The associated cost 
components, obtained from literature published in Japan, were inpatient, outpa-
tient, and medication for biliary tract cancer as well as those for palliative care. 
We estimated cost-effectiveness per quality-adjusted life year (QALY) at a time 
horizon of thirty two months. An annual discount for cost and outcome was not 
considered. Results: The model demonstrate no statistical significance in the 
hazard ratio of 0.625, as compared to an actual ratio of 0.63 (95% confidence inter-
val: 0.51–0.77) retrieved from the clinical trial. The base case outcomes indicated 
that combination therapy would be more cost-effective than monotherapy when 
the incremental cost-effectiveness ratio (ICER) was approximately 720,000 YEN 
per QALY gained, retrospectively. A tornado diagram depicting the deterministic 
sensitivity analysis of the ICER revealed that the death rate resulting from the 
combination therapy influenced the base case, but robustness of the base case 
was identified. A probabilistic analysis resulting from 5,000 Monte Carlo simula-
tions demonstrated efficacy at willingness to pay (WTP) thresholds of 5,000,000 
YEN per QALY gained in approximately 95% of the population. cOnclusiOns: 
In Japan, combination therapy is a cost-effective treatment option for advanced 
biliary tract cancer.
PCN139
HEad to HEad ECoNomiC EvaLuatioN of two GENomiC PRofiLEs of 
RECuRRENCE Risk foR BREast CaNCER, mammaPRiNt vERsus oNCotyPE 
dx, iN sPaiN
Crespo C.1, Seguí M.Á2, Cortés J.3, Lluch A.4, Brosa M.5, Becerra V.6, Chiavenna S.M.6, Gracia A.6
1University of Barcelona, Barcelona, Spain, 2Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, 
Spain, 3Hospital Universitario Vall d’Hebron, Barcelona, Spain, 4Hospital Clinico Universitario, 
Valencia, Spain, 5Oblikue Consulting, Barcelona, Spain, 6Ferrer Internacional, Barcelona, Spain
Objectives: Cost effectiveness analysis of MammaPrint in the diagnosis of early 
breast cancer from the Spanish NHS perspective. MethOds: Markov model 
nomic evaluation. Sensitivity analyses were conducted to explore the uncertainties 
surrounding the assumptions. Results: Abiraterone plus prednisolone indicated 
higher QALYs than prednisolone alone, though it was more expensive. In the base-
case analysis, ICER for abiraterone plus prednisolone exceeded JPY 10 million (EUR 
80,000) per QALY gained. The one-way sensitivity analysis for discount rate (0 to 
4%) showed no affects on the results. cOnclusiOns: The present study concludes 
that the ICER may be more than JPY 10 million. Further deliberate discussion on 
cost-effectiveness of abiraterone in Japan is needed to consider the Japanese price 
and clinical outcomes.
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ECoNomiC EvaLuatioN of HPv vaCCiNatioN PRoGRam iN soutH koREa
Kim J., Kim Y., Ahn J., Kim Y., Park J.
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
Objectives: To assess the cost-effectiveness of a national HPV vaccination pro-
gram that vaccinates 12 year-old girls with cervical cancer screening and the only 
current cervical cancer screening. MethOds: We analyzed the effect of HPV infec-
tion reduction by HPV vaccination on reduction of CIN and cervical cancer and 
finally conducted cost-utility analysis applying QALYs to which takes into account 
life span expansion and the quality of life. With the societal perspective, patient 
time costs, caregiver costs, and transportation costs were all considered as well as 
medical costs. Markov model was used with one year cycle and life time analysis 
period. Markov states in this model were classified well, HPV infection, CIN 1, CIN 
2/3, cervical cancer (initial cancer), follow-up cervical cancer, recurrent/persistent 
cancer, follow-up recurrent/persistent cancer and death. The HPV infection was 
limited to infections caused by HPV specific types 16 and 18. Results: When HPV 
vaccination program is introduced to 12-year old cohort, it was indicated that 
cervical cancer patients with HPV vaccination program would be 2,042 patients 
and cervical cancer patients with present screening program 3,709. It results that 
cervical cancer patients would be decreased to 1,667 by HPV vaccination. From 
this, it was estimated that all the cohorts would get an additional life expectancy 
of 1,648 LYG and quality adjusted life years of 1,849 QALYs. According to cost-utility 
analysis result, additional 1849 QALYs cost KRW 59.8 billion when HPV vaccination 
program implement, and the incremental cost-utility ratio was estimated to be 
KRW 32 million per a QALY. Considering the threshold of Korean cost-effective-
ness, the vaccination program is decided not to be cost-effective. cOnclusiOns: 
Though the HPV vaccination program for 12-year old girls was not cost-effective at 
the current condition of Korea, it is advisable to consider that cost-effectiveness 
varies sensitively.
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Cost utiLity aNaLysis of EvERoLimus iN tHE tREatmENt of mEtastatiC 
RENaL CELL CaNCER iN tHE NEtHERLaNds
Mihajlović J., Minović I., Bruinsma A., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: Metastatic renal cell cancer (mRCC) is becoming an important part of 
Dutch health care expenditure due to expensive pharmaceutical options for disease 
control and lack of adequate prevention methods. New targeted therapeutics, such 
as sunitinib, sorafenib and everolimus, have recently emerged with relevant benefits 
on progression-free survival (PFS) for mRCC patients. This study aims to assess 
the cost-effectiveness of the most recent of these introductions, i.e. everolimus, 
in comparison to best supportive care in second line treatment of mRCC patients 
in The Netherlands. MethOds: A Markov model was designed in line with Dutch 
treatment protocols. Transitions between health states were modeled by time-
dependent probabilities extracted from published Kaplan-Meier curves for PFS and 
overall survival (OS). The cohorts were followed over 18 cycles, each cycle lasting 8 
weeks. Annual discount rates of 1.5% for health and 4% for costs were applied and 
a health-care perspective was taken. One-way and probabilistic sensitivity analyses 
(PSA) were performed to test the robustness and uncertainty around the base-case 
estimate. Results: The incremental cost-effectiveness ratio (ICER) for everolimus 
was esimated at € 92,258/QALY. Sensitivity analysis identified the hazard multi-
plier, an estimate of OS gain, as the main driver of everolimus’ cost-effectiveness. 
Through PSA a wide 95% confidence interval around the base-case ICER estimate 
was revealed (€ 49,677 - € 453,941/QALY). Additionally, at the threshold of three times 
GDP per capita (€ 95,700 in The Netherlands) everolimus had a 54% probability of 
being cost-effective. cOnclusiOns: The base-case ICER was just below the upper 
cost-effectiveness limit recommended by WHO, indicating that everolimus might 
be a cost-effective option in the Dutch setting. However, reasonable uncertainty of 
the main finding resulted from everolimus’ unpredictable gain in OS. Efforts should 
be undertaken to perform an integral assessment of the economic attractiveness 
of all current and new therapeutics in mRCC.
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Cost-utiLity aNaLysis (Cua) of diffERENt stRatEGiEs to tREat NEwLy 
diaGNosEd LoCaLLy CoNfiNEd Low-Risk PRostatE CaNCER (LCLRPC) iN 
GERmaNy: REsuLts of tHE HaRow study
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
Objectives: The optimal treatment choice for preserving quality of life (QoL) of 
the about 64,000 men diagnosed with prostate cancer each year in Germany still 
remains unclear. The objectives therefore were to estimate cost utility under day-
to-day conditions of caring for men in Germany with newly diagnosed LCLRPC 
using hormonal therapy (HT), active surveillance (AS), radiotherapy (RT), operation 
(OP), or watchful waiting (WW) – HAROW. MethOds: The long-term observational 
multi-centre HAROW study combined data collection from urologists (clinical data; 
utilized outpatient medical services, OMS) and from patients (employment status, 
QoL by EQ-5D, numerous health resource use items). Resource use was valued by 
year 2010 official prices in € . Direct costs (DC) were given by hospital treatment, 
